@
See the future of skin cancer assessment
Don’t miss Skin Analytics CEO Neil Daly on the HLTH main stage, as he shares our vision for the future of skin cancer diagnosis.
What’s next for AI in dermatology?
DERM Zero is a world-first: Class III regulated AI delivering autonomous skin cancer assessment from a standard smartphone.
Built on six years of NHS deployment, DERM Zero enables healthcare providers in primary care, pharmacy or community settings, to perform clinical grade skin cancer checks in seconds. No hospital appointment. No specialist equipment.
Skin Analytics and our partners will be sharing more about the role of autonomous AI in improving patient access to skin cancer diagnosis.
Find us at the following sessions:
Skin Analytics CEO Neil Daly reveals our latest breakthrough and its impact on how patients access dermatology
Skin Analytics CEO Neil Daly joins Tandem Health’s Lukas Saari and Nabla’s Laurie Soffiati to discuss how leading AI companies are leveraging the EU’s regulatory foothold to compete, scale, and endure?
Marcela Vizcaychipi, CCIO at Chelsea and Westminster NHS Foundation Trust presents a case study on deploying Skin Analytics’ DERM, a highly regulated AI as a Medical Device for cancer detection in to urgent skin cancer pathways, and its impact on capacity, access and clinical safety
Skin Analytics CEO Neil Daly will share examples of how providers are using AI to autonomously discharge patients without review by a clinician in primary, acute, and at-home pathways.
Skin Analytics Head of NHS Commercial Darren Jalink shares a case study on the deployment of DERM in a high volume NHS skin cancer pathway.
